Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.

Muscle Study Group..

Neurology. 2001 Nov 13;57(9):1566-70. Erratum in: Neurology 2002 Jan 22;58(2):334.

PMID:
11706093
2.

Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis.

Muscle Study Group..

Neurology. 2004 Aug 24;63(4):718-20.

PMID:
15326251
3.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
5.

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.

Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A; European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group..

Mult Scler. 2003 Aug;9(4):342-8.

PMID:
12926838
6.

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.

Walter MC, Lochmüller H, Toepfer M, Schlotter B, Reilich P, Schröder M, Müller-Felber W, Pongratz D.

J Neurol. 2000 Jan;247(1):22-8.

PMID:
10701893
7.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
9.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators..

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 .

PMID:
18315940
11.

A pilot randomized trial of oxandrolone in inclusion body myositis.

Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM.

Neurology. 2002 Apr 9;58(7):1081-7.

PMID:
11940697
12.

Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.

Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, Sandrock A; Avonex CIDP Study Group..

Neurology. 2010 Feb 23;74(8):651-7. doi: 10.1212/WNL.0b013e3181d1a862.

PMID:
20177118
13.

Interferon beta-1a as an investigational treatment for CIDP.

Vallat JM, Hahn AF, Léger JM, Cros DP, Magy L, Tabaraud F, Bouche P, Preux PM.

Neurology. 2003 Apr 1;60(8 Suppl 3):S23-8.

PMID:
12707419
15.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
16.

Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis.

Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M.

Neurol Sci. 2011 Oct;32(5):841-7. doi: 10.1007/s10072-011-0657-6.

PMID:
21695654
17.

Pilot trial of etanercept in the treatment of inclusion-body myositis.

Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR.

Neurology. 2006 Jan 24;66(2 Suppl 1):S123-4.

PMID:
16432140
18.

Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.

LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A.

Clin Ther. 2007 Aug;29(8):1579-90; discussion 1577-8.

PMID:
17919541
19.

Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.

Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.

Mult Scler. 2009 Aug;15(8):965-76. doi: 10.1177/1352458509105229.

PMID:
19465443
20.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
Items per page

Supplemental Content

Support Center